Award Number: W81XWH-05-1-0270

TITLE: Gene Therapy for Osteolytic Breast Cancer Bone Metastasis

PRINCIPAL INVESTIGATOR: Selvarangan Ponnazhagan, Ph.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham
Birmingham, AL 35294-0109

REPORT DATE: June 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 01-06-2007
2. REPORT TYPE Annual
3. DATES COVERED (From - To) 1 Jun 2006 – 31 May 2007

4. TITLE AND SUBTITLE Gene Therapy for Osteolytic Breast Cancer Bone Metastasis

5a. CONTRACT NUMBER
5b. GRANT NUMBER W81XWH-05-1-0270
5c. PROGRAM ELEMENT NUMBER
5d. PROJECT NUMBER
5e. TASK NUMBER
5f. WORK UNIT NUMBER

6. AUTHOR(S) Selvarangan Ponnazhagan, Ph.D.
E-Mail: pons@uab.edu

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Alabama at Birmingham
Birmingham, AL 35294-0109

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES – Original contains colored plates: ALL DTIC reproductions will be in black and white.

14. ABSTRACT
Bone is the frequent metastatic site for human breast cancer resulting in significant morbidity and mortality in patients with advanced disease. Osteoprotegerin (OPG) is a 'decoy' receptor that competes with RANK for RANKL, thus, modulating the effects of RANKL. However, during the metastatic events involving cancer and stromal cell interaction, endogenous OPG levels are markedly reduced. Thus, OPG remains an effective molecule for future therapies for bone metastasis. We sought to achieve sustained effects of OPG combining cell therapy and gene therapy approaches. The aims were to determine therapeutic effects of stable OPG expression by rAAV gene therapy in a murine model of breast cancer bone metastasis, and to determine the synergistic effects of OPG gene therapy with bisphosphonate therapy in a murine model of breast cancer bone metastasis. So far, we produced high-titer recombinant AAV vectors encoding osteoprotegerin, and tested the feasibility of MSC therapy for reducing osteolysis in bone initiated by cancer growth. Also we established a method for bone homing of ex vivo cultured MSC by transient expression of α4β1 integrin. Continuation of the ongoing studies in to next year will provide valuable information on therapeutic effects of this therapy for breast cancer bone metastasis.

15. SUBJECT TERMS Osteolysis, osteoprotegerin, mesenchymal stem cells, gene therapy, adeno-associated virus

16. SECURITY CLASSIFICATION OF:

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>b. ABSTRACT</th>
<th>c. THIS PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
</tbody>
</table>

17. LIMITATION OF ABSTRACT
UU

18. NUMBER OF PAGES 7

19a. NAME OF RESPONSIBLE PERSON
USAMRMC

19b. TELEPHONE NUMBER (include area code)

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. 239.18
# Table of Contents

- Introduction ........................................................................................................... 4
- BODY ....................................................................................................................... 4
- Key Research Accomplishments ........................................................................... 7
- Reportable Outcomes ............................................................................................ 7
- Conclusions ............................................................................................................ 7
- References ............................................................................................................. 7
- Appendices ............................................................................................................. 7
INTRODUCTION
Bone is the frequent metastatic site for human breast cancer resulting in significant morbidity and mortality in patients with advanced disease. A vicious cycle, arising due to the interaction of cancer cells and the bone microenvironment results in the upregulation of factors promoting osteoclastogenesis and osteolytic bone destruction. Thus, osteolysis and tumor cell accumulation can be inhibited by interrupting one or more of the steps involved in the cycle. The major treatment to reduce the burden of bone metastasis in breast cancer patients is bisphosphonate therapy. Despite significant efforts to improve the potency of bisphosphonates, the complications are only retarded but not prevented. Thus, while improving the formulations of bisphosphonate compounds, development of newer therapies that can both ameliorate the threshold of bone destruction and increase survival of patients with metastatic breast disease will be highly beneficial.

A better understanding of the molecular events in breast cancer osteolytic bone destruction indicates that the receptor activator of nuclear factor κ B ligand (RANKL), produced by osteoblasts, activated T cells and marrow stromal cells stimulates the recruitment, differentiation, and activation of osteoclasts by binding to RANK. Osteoprotegerin (OPG) is a “decoy” receptor that competes with RANK for RANKL, thus, modulating the effects of RANKL. However, during the metastatic events involving cancer and stromal cell interaction, endogenous OPG levels are markedly reduced. Thus, OPG remains an effective molecule for future therapies for bone metastasis. To achieve sustained effects of OPG, gene therapy is more powerful than pharmacological therapies. Since the process of bone metastasis in breast cancer is a secondary event that occurs in late-stage disease or during recurrence, genetic therapies aimed at controlling this process should be both sustained and localized. Thus, for sustained expression of therapeutic levels of OPG, a vector capable of stable expression of the transgene without vector-associated toxicity and immunity is ideal. The adeno-associated virus vectors (AAV) are more promising to this end. With recombinant AAV vectors, it is possible to obtain significant therapeutic advantage by either systemic or bone-targeted transduction and can be combined with bisphosphonate treatment for synergistic effects.

The proposed specific aims of the project are:
1) To determine the therapeutic effects of stable OPG expression by rAAV gene therapy in a murine model of breast cancer bone metastasis, and
2) To determine the synergistic effects of OPG gene therapy with bisphosphonate therapy in a murine model of breast cancer bone metastasis.

BODY
Recombinant AAV-mediated, systemically stable expression of osteoprotegerin inhibits osteolytic bone damage. The purpose of the present study was to determine the effect of sustained level of OPG.Fc in a therapeutic model of osteolytic breast cancer. 6 weeks old female athymic nude mice (n=24) were injected intra-cardiac 2 X 10^5 MDA-MB-435 breast cancer cells expressing firefly luciferase. 3 mice served as normal age matched control and received no tumor cells or treatment. Widespread skeletal metastases were confirmed 7 days after the intra-cardiac injection after bioluminescence imaging. 16 out of 24 mice showed clear signs of bone metastasis. At this point 8 out of 16 positive mice were administered intra-muscular delivery of 3 X 10^{11} virus particles of AAV-OPG.Fc and rest of the mice received 3 X 10^{11} particles of AAV-GFP. Therapeutic benefits were determined 4 weeks after the delivery of the virus particles. Bioluminescence imaging showed significant reduction in tumor growth in the OPG.Fc treated mice compared to GFP treated mice. No significant difference was observed in bioluminescence from any extra-osseous metastasis between OPG.Fc and GFP treated mice. Micro-computerized tomography (µCT) analysis indicated significant decline in bone to tissue volume ratio and trabecular bone density in the tumor challenged untreated or GFP treated animals. OPG.Fc treatment restored the bone to tissue volume ratio and significantly enhanced the trabecular bone density. Ki-67 immunostaining showed presence of proliferating tumor cells in the tibia of both OPG.Fc treated and GFP treated animals. PARP-p85
immunostaining was detected only in the tumor cells which are trapped inside the trabeculae of the newly formed cancellous or trabecular bone in the metaphyses and not in the tumor cells those were present in the diaphyses suggesting indirect killing of tumor cells by OPG.Fc. A significant loss in body weight was observed in both OPG.Fc treated and GFP treated mice which suggest inability of OPG.Fc to influence any soft tissue metastasis. Moreover, OPG.Fc treatment resulted into overproduction of bone, which may require introduction of regulated gene expression system. We suggest that OPG.Fc in combination with chemotherapy may prove useful for the management of osteolytic bone metastasis.

Doxorubicin induces cancer cell apoptosis independently of TRAIL blocking by OPG. Since TRAIL binding property of OPG inhibits apoptosis of metastasized cancer cells in the bone marrow, we reasoned that combination of OPG therapy with chemotherapy using drugs capable of inducing cancer cell apoptosis, independently of TRAIL pathway, would provide great synergy. To determine this, we used doxorubicin, a known chemotherapeutic drug commonly given to patients with breast cancer. Human osteolytic cancer cell line line, CAG, was seeded at a concentration of 2x10^5 cells/well of a 6-well dish and treated with 50 ng/ml TRAIL, 1 µg/ml purified OPG.Fc and 20 ng/ml doxorubicin in various combinations. The cells were harvested after 48 hours, washed in PBS and subjected to Trypan Blue staining for cell viability. Cell proliferation was determined by MTT assay and immunostaining performed in a cytospin using cell proliferation marker Ki-67 and apoptosis marker PARP-p85 fragment. Results of these studies, shown in figures below demonstrate that although in the presence of OPG, TRAIL-mediated apoptosis is significantly prevented, apoptotic effects of DOX was totally

**Doxorubicin induces cancer cell apoptosis independently of TRAIL blocking by OPG.** Since TRAIL binding property of OPG inhibits apoptosis of metastasized cancer cells in the bone marrow, we reasoned that combination of OPG therapy with chemotherapy using drugs capable of inducing cancer cell apoptosis, independently of TRAIL pathway, would provide great synergy. To determine this, we used doxorubicin, a known chemotherapeutic drug commonly given to patients with breast cancer. Human osteolytic cancer cell line line, CAG, was seeded at a concentration of 2x10^5 cells/well of a 6-well dish and treated with 50 ng/ml TRAIL, 1 µg/ml purified OPG.Fc and 20 ng/ml doxorubicin in various combinations. The cells were harvested after 48 hours, washed in PBS and subjected to Trypan Blue staining for cell viability. Cell proliferation was determined by MTT assay and immunostaining performed in a cytospin using cell proliferation marker Ki-67 and apoptosis marker PARP-p85 fragment. Results of these studies, shown in figures below demonstrate that although in the presence of OPG, TRAIL-mediated apoptosis is significantly prevented, apoptotic effects of DOX was totally
unaffected in the presence of OPG. Thus, combination of DOX with bone-targeted OPG therapy is expected to prevent osteolytic bone damage and promote tumor cell apoptosis to increase survival.

Tumoricidal effects of doxorubicin is independent of TRAIL binding of OPG. Human osteolytic cancer cell line, CAG, were seeded at a concentration of 2 X 10^5 cells/well of a 6 well dish and treated with 50ng/ml TRAIL, 1 µg/ml mouse OPG.Fc and 20ng/ml doxorubicin (DOX) in various combinations in duplicates. MTT assay for cell proliferation was performed 48 hrs later.

Proliferation and apoptosis of human osteolytic cancer cell line following treatments with OPG, DOX and TRAIL combinations. Human osteolytic cell line CAG was seeded at a concentration of 2 X 10^5 cells/well of a 6 well dish and treated with 50ng/ml TRAIL, 1 µg/ml mouse OPG.Fc and 20ng/ml doxorubicin in various combinations in duplicates. Cells were harvested after 48 hours, centrifuged to pellet the cells, washed in PBS and analyzed by immunostaining for cell proliferation marker (Ki-67-Alexa fluor-594,red) and apoptosis marker (PARP-p85 fragment, Alexa Fluor-488, green).
KEY RESEARCH ACCOMPLISHMENTS

- Demonstrated that systemically stable expression of OPG using rAAV is capable of decreasing osteolytic bone damage in a mouse model of metastatic breast cancer.
- Established that doxorubicin acts independently of the influence of OPG on TRAIL binding.

REPORTABLE OUTCOMES

(Papers published or communicated)


(Results presented in conferences)


CONCLUSIONS

We have successfully determined that sustained expression of OPG using recombinant AAV greatly reduces osteolytic bone damage in a mouse model of bone metastatic breast cancer. We will continue to determine if the same therapy using mesenchymal stem cell vehicle would provide better benefits. In addition we will combine the use of chemotherapy, targeted to the cancer cells in addition to inhibiting osteoclast activity by OPG. Continuation of the ongoing studies in to next year will provide valuable information on therapeutic effects of this therapy for breast cancer bone metastasis.

PERSONNEL RECEIVING PAY FROM THIS GRANT

Selvarangan Ponnazhagan, Ph.D.
Tatyana Isayeva, M.D., Ph.D.

REFERENCES

N/A

APPENDICES

N/A